PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

  title={PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma},
  author={David King and Daniel Yeomanson and Helen E. Bryant},
  journal={Journal of Pediatric Hematology/Oncology},
Neuroblastoma is the most common extracranial cancer in childhood. High-risk neuroblastoma continues to have a poor prognosis and there is an urgent need to design biologically based therapies that specifically target the pathways responsible for malignant transformation and progression. One such pathway is the PI3K/Akt/mTOR pathway. In this article we outline the evidence for aberrant activation of the PI3K/Akt/mTOR pathway in neuroblastoma and discuss the possible mechanisms which mediate it… 
Polo-like kinase 4 mediates epithelial–mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway
The study showed the expression level of PLK4 in NB tissues was remarkably upregulated and high expression ofPLK4 was negatively correlated with clinical features and survival, which suggested that PLK 4 could be a potential tumor-promoting factor of NB.
A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
The RAS-MAPK pathway’s general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling are discussed.
Targeting gallbladder cancer: a pathway based perspective
A better understanding of the pathways involved in GBC pathogenesis will aid clinicians in the prognosis, diagnosis and treatment of patients as they permit the understanding of onset and progression of the disease.
Specific Inhibition of GSK-3β by Tideglusib: Potential Therapeutic Target for Neuroblastoma Cancer Stem Cells
Tideglusib proved to be an effective in vitro and in vivo treatment for neuroblastoma cell lines and may hence serve as a potential adjuvant therapeutic agent for this aggressive nervous system tumor.
Molecular targeting therapies for neuroblastoma: Progress and challenges
This review provides a comprehensive overview of the molecular targeted therapies under preclinical and clinical investigations, particularly those targeting ALK signaling, MDM2, PI3K/Akt/mTOR and RAS‐MAPK pathways, as well as epigenetic regulators, and gives insights on the use of combination therapies involving novel agents that target various pathways.
The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma
Rapamycin and Triciribine proved to be effective in the in vitro treatment of glioblastoma and neuroblastoma, by targeting their CSC population, by inhibiting this pathway to prevent recurrence in various cancer subtypes.
Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer.
Current knowledge of miRNAs' regulatory roles of PI3K/AKT signaling in CRC pathogenesis are summarized and novel biomarkers for new patient diagnosis and obtaining clinically invaluable information from post-treatment CRC patients are summarized.
PKN2 Regulates the Survival of PC12 Cells by Activating the AKT/mTOR Pathway
Preliminary experiments showed that protein kinase N2, a kind of serine/threonine-protein kinase, could promote the phosphorylation levels of AKT and mTOR and provide theoretical evidence for the treatment of peripheral nerve damage.
The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer
The relationship between gene mutations and overexpression and clinicopathological variable of KIT, PI3K , and AKT in breast cancer is investigated and the drugs that inhibit the RTK signaling are being tested in clinical trials for the treatment of breast cancer.


Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration
The role of the PI3K/Akt/mTOR pathway in pediatric solid tumors is examined, the novel agents being explored to target this pathway are reviewed, and the potentialrole of the inhibition of this pathway in the clinical development of these agents in children is explored.
Development of PI3K inhibitors: lessons learned from early clinical trials
This Review focuses on early clinical and translational data related to inhibitors of the PI3K/AKT/mTOR pathway, as these data will likely guide the further clinical development of such agents and describes predictive biomarkers explored in clinical trials and preclinical mechanisms of resistance.
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
  • H. Burris
  • Biology, Medicine
    Cancer Chemotherapy and Pharmacology
  • 2012
Current preclinical and clinical evidence suggest that inhibitors of the PI3K/AKT/mTOR pathway could have utility in combination with other anticancer therapies to circumvent resistance by cancer cells.
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
It is demonstrated that a drug currently being tested in clinical trials for solid tumors improves survival by targeting the MYCN protein, and suggested that NVP-BEZ235 should be tested in children with high-risk, MYCN-amplified neuroblastoma.
Novel Agents Targeting the IGF-1R/PI3K Pathway Impair Cell Proliferation and Survival in Subsets of Medulloblastoma and Neuroblastoma
The studies demonstrate the potential of targeting the IGF-1R/PI3K signaling axis in embryonal tumors and contribute to the development of urgently required new targeted therapies for embryonal tumor treatment.
Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
The findings show that cancer cells can be sensitized for chemotherapy induced cell death by NVP-BEZ235-mediated modulation of VDAC1, and suggest that sequential dosing has important implications for the general design of combination therapies involving molecular targeted approaches towards the PI3K/Akt/mTOR signaling network.
Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma
PI103 primes neuroblastoma cells for TRAIL-induced apoptosis by shifting the balance toward proapoptotic Bcl-2 family members and increased mitochondrial apoptosis, and PI3K inhibitors represent a novel promising approach to enhance the efficacy of TRAil-based treatment protocols in Neuroblastoma.
Activation of Akt predicts poor outcome in neuroblastoma.
Evidence is provided for the first time evidence that phosphorylation of Akt at serine 473 and/or threonine 308, S6 ribosomal protein, and ERK frequently occurs in primary neuroblastoma, and it is identified as a novel prognostic indicator of decreased event-free or overall survival in Neuroblastoma.